Roche’s star MS medicine Ocrevus wins EU approval

ZURICH (Reuters) – The European Union approved Roche’s multiple sclerosis medicine Ocrevus, one the Swiss company’s key new drugs that likely neared $1 billion in revenue in its first nine months on the U.S. market.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply